Steve Bannon, a former White House adviser to President Donald Trump, has said agents from U.S. Immigration and Customs Enforcement (ICE) will be at the polls during November's midterm elections. "You ...

Joe Grantham is a contributor from the UK with a degree in Classical Studies. His love for gaming is only rivaled by a deep passion for medieval history, which often seeps into his articles. With over ...

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

As of December 2025, there is no approved fourth federal stimulus check. Former President Donald Trump has proposed a new round of payments, but this has not been approved by Congress. Arizona has ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

In mid-December 2025, an image (archived) circulated online purportedly showing U.S. President Donald Trump using a walker as a mobility aid. Keith Edwards, a Democratic political strategist, posted ...

What is it with lawyers and AI? We don’t know, but it feels like an inordinate number of them keep screwing up with AI tools, apparently never learning from their colleagues who get publicly crucified ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Lynn White was out of options. Allegedly behind on rent payments to her trailer park in Long Beach, California, and facing an eviction notice, she worked with a lawyer from a local tenant advocacy ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...